La Monica S et al (2019) Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. J Experim Clin Cancer Res. https://doi.org/10.1186/s13046-019-1240-x

Article  Google Scholar 

Schiller JH et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98

Article  CAS  PubMed  Google Scholar 

Tan CS, Gilligan D, Pacey S (2015) Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol 16(9):E447–E459

Article  CAS  PubMed  Google Scholar 

Camidge DR, Pao W, Sequist LV (2014) Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 11(8):473–481

Article  CAS  PubMed  Google Scholar 

Engelman JA et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039–1043

Article  CAS  PubMed  Google Scholar 

Nguyen KSH, Kobayashi S, Costa DB (2009) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10(4):281–289

Article  CAS  PubMed  PubMed Central  Google Scholar 

Passaro A et al (2017) Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment. Pharmacol Res 117:406–415

Article  CAS  PubMed  Google Scholar 

Yun CH et al (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105(6):2070–2075

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tan CS et al (2018) Third generation EGFR TKIs: current data and future directions. Mol Cancer 17:1–14

Article  Google Scholar 

Westover D et al (2018) Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 29(suppl–1):i10–i19

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou BBS et al (2006) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10(1):39–50

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang YC et al (2014) Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation. Int J Biol Sci 10(7):702–714

Article  CAS  PubMed  PubMed Central  Google Scholar 

Edwards DR, Handsley MM, Pennington CJ (2008) The ADAM metalloproteinases. Mol Aspects Med 29(5):258–289

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arribas J, Esselens C (2009) ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des 15(20):2319–2335

Article  CAS  PubMed  Google Scholar 

Kenny PA, Bissell MJ (2007) Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Investig 117(2):337–345

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang Z, Tam KY (2018) Combination strategies using EGFR-TKi in NSCLC therapy: learning from the gap between pre-clinical results and clinical outcomes. Int J Biol Sci 14(2):204–216

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kataoka H (2009) EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. J Dermatol Sci 56(3):148–153

Article  CAS  PubMed  Google Scholar 

DasGupta S et al (2009) Current perspective of TACE inhibitors: A review. Bioorg Med Chem 17(2):444–459

Article  CAS  PubMed  Google Scholar 

Fridman JS et al (2007) Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res 13(6):1892–1902

Article  CAS  PubMed  Google Scholar 

Coussens LM, Fingleton B, Matrisian LM (2002) Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295(5564):2387–2392

Article  CAS  PubMed  Google Scholar 

Zhang YH et al (2004) Characterization of (2R, 3S)-2-(amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme. Int Immunopharmacol 4(14):1845–1857

Article  CAS  PubMed  Google Scholar 

Kwok HF et al (2014) Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy. Protein Eng Des Sel 27(6):179–190

Article  CAS  PubMed  Google Scholar 

Ye J et al (2017) Anti-tumor effects of a ‘human & mouse cross-reactive’ anti-ADAM17 antibody in a pancreatic cancer model in vivo. Eur J Pharm Sci 110:62–69

Article  CAS  PubMed  Google Scholar 

Soto-Gamez A et al (2020) A bispecific inhibitor of the EGFR/ADAM17 axis decreases cell proliferation and migration of EGFR-dependent cancer cells. Cancers 12(2):411. https://doi.org/10.3390/cancers12020411

Article  CAS  PubMed  PubMed Central  Google Scholar 

Animal Research (2010) Reporting in vivo experiments: The ARRIVE guidelines. Exp Physiol 95(8):842–844

Article  Google Scholar 

Yao S, Fan LYN, Lam EWF (2018) The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance. Semin Cancer Biol 50:77–89

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Moraes GN et al (2016) Insights into a critical role of the FOXO3a-FOXM1 axis in DNA damage response and genotoxic drug resistance. Curr Drug Targets 17(2):164–177

Article  Google Scholar 

Sequist LV et al (2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26(15):2442–2449

Article  CAS  PubMed  Google Scholar 

Minari R, Bordi P, Tiseo M (2016) Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance. Transl Lung Cancer Res 5(6):695–708

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turke AB et al (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1):77–88

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu SG, Shih JY (2018) Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer 17(1):38

Article  PubMed  PubMed Central  Google Scholar 

Rios-Doria J et al (2015) A monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and Non-EGFR-mediated pathways. Mol Cancer Ther 14(7):1637–1649

Article  CAS  PubMed  Google Scholar 

Sharma A et al (2016) Secretome signature identifies ADAM17 as novel target for radiosensitization of non-small cell lung cancer. Clin Cancer Res 22(17):4428–4439

Article  CAS  PubMed  Google Scholar 

Saad MI et al (2019) ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer. Embo Mol Med 11(4):e9976

Article  PubMed  PubMed Central  Google Scholar 

Nagano T, Tachihara M, Nishimura Y (2018) Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells 7(11):212

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tomasello C et al (2018) Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. Crit Rev Oncol Hematol 123:149–161

Article  PubMed  Google Scholar 

Li J, Kwok HF (2020) Current strategies for treating NSCLC: from biological mechanisms to clinical treatment. Cancers (Basel) 12(6):1587

Article  CAS  PubMed